 Life Science Investor Mandates
(May 10 - May 16
)
|
|
|
|
|
Seeking to Provide Seed Capital to USA-Based Therapeutics Opportunities
|
|
Seeks Early to Mid-Stage Therapeutics Partnering Opportunities, Capable of Investing Up to $100M
|
|
Seeking to Invest in Therapeutic Technologies that Solve Problems Within Genetically Driven Diseases
|
|
Works on Early and Late-Stage Deals in Medical Devices and Therapeutics with China Market Potential
|
|
LSN's Sourcing & Ranking Service (SRS) provides clients with an opportunity to quickly source, vet, rank and engage with partners that are licensing global technology assets.
|
|
Click to see investors that are a fit for your product and stage of development
|
|
Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you
|
|
Click here if you want to receive free, targeted early stage dealflow for your life science investment firm
|
|
 |
|
 |
 Even with the RESI Boston conference less than 3 weeks away, the upcoming conference continues to attract an international crowd of early-stage companies and investors. In last week's newsletter, we discussed how over 1/3 of the registered attendees are coming from firms based outside of the USA. For this particular event, Life Science Nation (LSN) has been working closely with the Korea Trade-Investment Promotion Agency (KOTRA) to showcase innovative technologies from South Korea across therapeutics, medical devices, diagnostics, and digital health.
The Korean biotech ecosystem has certainly been growing in all aspects. This year, the government has pledged to invest over $328M (USD) to support the development of new biotech. For many years, South Korea has been well-established as a R&D hub - beyond the capital city of Seoul, other cities to keep an eye on include Songdo International City (home to large biotech companies, including Celltrion and Samsung BioLogics) and Daejeon (home to KAIST and a newly established biocluster, the DAEJEON Bio Venture Town). An increasing number of pharmaceutical groups are seeking innovations globally for in-licensing and equity investment. Some groups, like Yuhan Corporation, are planning to expand their operations in the USA, among other developed nations...
|
|
|
|
An interview with
Andy Li,
CEO & President, Biosense Global
Investor Research Analyst, LSN
|
|
Earlier this week, I had the pleasure of speaking with Dr. Andy Li, the founding partner of Biosense Global LLC. Andy has attended nearly every RESI event in the last 2 years. RESI is a partnering event that enables early-stage life science, MedTech and digital health companies to meet and interact with investors and strategic partners based on mutual fit. Recently, we learned that Biosense Global has invested in two companies that Andy first met at RESI.
In this interview, Andy discusses his perspectives on his RESI experiences, Biosense Global's investments in companies attended RESI, and some suggestions for fundraising CEOs.
Jessica: To begin, please tell us a little bit about your background and your fund.
Andy: My name is Andy Li, and I am the founding partner of Biosense Global LLC. I have more than 25 years of biomedical research and biopharmaceutical industry experience with proven track records in global drug development in multiple therapeutic areas, alliance management, and business development. Currently, Biosense Global invests in early to mid-stage biopharma and Medtech projects. With our R&D facilities in China, in-licensing assets from the U.S. and Europe to China would be an important consideration...
|
 |
In recent years, big pharma companies have begun looking outwards for innovative new therapeutics to add to their pipelines. RESI has become a venue for these major players to make connections with early stage biotech companies, and RESI includes a panel on
Big Pharma to provide entrepreneurs with an opportunity to learn directly from experienced pharma scouts on how to find the right partner and get a deal made.
This panel will feature five speakers from various big pharma companies. These panelists will shed some light on the process that big pharma goes through when sourcing early stage assets and advise startups on how they can best make a case for themselves. Panelists will also explore various trends within the therapeutics marketplace, what assets are of interest to their company, and what they think will be big in the future.
The panelists are:
- Aaron Schwartz, Director, R&D Innovation Sourcing, Novo Nordisk
- Brian Bronk, Head of External Innovation, Rare Diseases, Sanofi
- Murali Gopalakrishnan, Sr. Director, Head Search & Evaluation Neuroscience, AbbVie
- Nicola La Monica, Senior Director, Infectious Diseases and Vaccines Scientific Innovation, Johnson & Johnson Innovation, Boston
- Yvonne Kobayashi, Sr Director, Emerging Technology & Innovation, Eli Lilly & Co
|
|
|
Created & Produced by
|
 |
|
|
|
